Propel Bio Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Propel Bio Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,032	Closed	-$9.95M	–	18
2025 Q1	$9.95M	Sell	30,032 -13,000	-30%	-$4.27M	11.56%	2
2024 Q4	$13.3M	Hold	43,032	–	–	13.19%	2
2024 Q3	$9.13M	Hold	43,032	–	–	5.3%	7
2024 Q2	$12.1M	Hold	43,032	–	–	7.82%	4
2024 Q1	$11.5M	Buy	43,032 +13,000	+43%	+$3.06M	6.69%	4
2023 Q4	$6.95M	Buy	+30,032	New	+$5.26M	5.76%	4

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Propel Bio Management's MDGL Position: Q2 2025 in Review

Propel Bio Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 30,032 shares — an estimated $9.95M sold.

Propel Bio Management first reported a position in MDGL in Q4 2023 and held it in 6 quarters. The position peaked at $13.3M in Q4 2024. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

Propel Bio Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Propel Bio Management sold 30,032 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $9.95M.
Propel Bio Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Propel Bio Management's Madrigal Pharmaceuticals position peaked at $13.3M in Q4 2024.
305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Propel Bio Management's 13F filing for Q2 2025, filed 13 Aug 2025.